B. Stasiuk

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

P. Emery, J. Vencovský, A. Sylwestrzak, 2015, Annals of the rheumatic diseases.

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

P. Emery, J. Vencovský, A. Sylwestrzak, 2017, Rheumatology.

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

P. Emery, J. Vencovský, A. Sylwestrzak, 2017, Annals of the Rheumatic Diseases.

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB 4 or switching from reference etanercept to SB 4

P. Emery, J. Vencovský, A. Sylwestrzak, 2017 .

THU0150 Long-Term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients with Rheumatoid Arthritis: Comparison between Continuing SB4 and Switching from Etanercept Reference Product To SB4

P. Emery, J. Vencovský, A. Sylwestrzak, 2016 .

FRI0128 A Phase III Randomised, Double-Blind Clinical Study Comparing SB4, An Etanercept Biosimilar, With Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-Week Results)

P. Emery, J. Vencovský, A. Sylwestrzak, 2015 .